Literature DB >> 32826231

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia.

Melissa M Berrien-Elliott1, Amanda F Cashen2,3, Celia C Cubitt2, Carly C Neal2, Pamela Wong2, Julia A Wagner2, Mark Foster2, Timothy Schappe2, Sweta Desai2, Ethan McClain2, Michelle Becker-Hapak2, Jennifer A Foltz2, Matthew L Cooper2, Natalia Jaeger2, Sridhar Nonavinkere Srivatsan2, Feng Gao3, Rizwan Romee2, Camille N Abboud2,3, Geoffrey L Uy2,3, Peter Westervelt2,3, Meagan A Jacoby2,3, Iskra Pusic2,3, Keith E Stockerl-Goldstein2,3, Mark A Schroeder2,3, John DiPersio2,3, Todd A Fehniger1,3.   

Abstract

Natural killer (NK) cells are an emerging cancer cellular therapy and potent mediators of antitumor immunity. Cytokine-induced memory-like (ML) NK cellular therapy is safe and induces remissions in patients with acute myeloid leukemia (AML). However, the dynamic changes in phenotype that occur after NK-cell transfer that affect patient outcomes remain unclear. Here, we report comprehensive multidimensional correlates from ML NK cell-treated patients with AML using mass cytometry. These data identify a unique in vivo differentiated ML NK-cell phenotype distinct from conventional NK cells. Moreover, the inhibitory receptor NKG2A is a dominant, transcriptionally induced checkpoint important for ML, but not conventional NK-cell responses to cancer. The frequency of CD8α+ donor NK cells is negatively associated with AML patient outcomes after ML NK therapy. Thus, elucidating the multidimensional dynamics of donor ML NK cells in vivo revealed critical factors important for clinical response, and new avenues to enhance NK-cell therapeutics. SIGNIFICANCE: Mass cytometry reveals an in vivo memory-like NK-cell phenotype, where NKG2A is a dominant checkpoint, and CD8α is associated with treatment failure after ML NK-cell therapy. These findings identify multiple avenues for optimizing ML NK-cell immunotherapy for cancer and define mechanisms important for ML NK-cell function.This article is highlighted in the In This Issue feature, p. 1775. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 32826231      PMCID: PMC7710923          DOI: 10.1158/2159-8290.CD-20-0312

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  43 in total

Review 1.  Cytokine receptor signaling pathways.

Authors:  W J Leonard; J X Lin
Journal:  J Allergy Clin Immunol       Date:  2000-05       Impact factor: 10.793

Review 2.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

3.  GATA-3 is an important transcription factor for regulating human NKG2A gene expression.

Authors:  Alina I Marusina; Dae-Ki Kim; Louis D Lieto; Francisco Borrego; John E Coligan
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

4.  Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data.

Authors:  Kirsten E Diggins; P Brent Ferrell; Jonathan M Irish
Journal:  Methods       Date:  2015-05-13       Impact factor: 3.608

5.  Web-based analysis and publication of flow cytometry experiments.

Authors:  Nikesh Kotecha; Peter O Krutzik; Jonathan M Irish
Journal:  Curr Protoc Cytom       Date:  2010-07

6.  CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.

Authors:  Margery Gang; Nancy D Marin; Pamela Wong; Carly C Neal; Lynne Marsala; Mark Foster; Timothy Schappe; Wei Meng; Jennifer Tran; Maximilian Schaettler; Marco Davila; Feng Gao; Amanda F Cashen; Nancy L Bartlett; Neha Mehta-Shah; Brad S Kahl; Miriam Y Kim; Matthew L Cooper; John F DiPersio; Melissa M Berrien-Elliott; Todd A Fehniger
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

7.  Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity.

Authors:  Elena G Addison; Janet North; Ismail Bakhsh; Chloe Marden; Sumaira Haq; Samia Al-Sarraj; Reza Malayeri; R Gitendra Wickremasinghe; Jeffrey K Davies; Mark W Lowdell
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

Review 8.  Improving natural killer cell cancer immunotherapy.

Authors:  Melissa M Berrien-Elliott; Rizwan Romee; Todd A Fehniger
Journal:  Curr Opin Organ Transplant       Date:  2015-12       Impact factor: 2.640

9.  First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Authors:  Rizwan Romee; Sarah Cooley; Melissa M Berrien-Elliott; Peter Westervelt; Michael R Verneris; John E Wagner; Daniel J Weisdorf; Bruce R Blazar; Celalettin Ustun; Todd E DeFor; Sithara Vivek; Lindsey Peck; John F DiPersio; Amanda F Cashen; Rachel Kyllo; Amy Musiek; András Schaffer; Milan J Anadkat; Ilana Rosman; Daniel Miller; Jack O Egan; Emily K Jeng; Amy Rock; Hing C Wong; Todd A Fehniger; Jeffrey S Miller
Journal:  Blood       Date:  2018-02-20       Impact factor: 25.476

Review 10.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Authors:  Pascale André; Caroline Denis; Caroline Soulas; Clarisse Bourbon-Caillet; Julie Lopez; Thomas Arnoux; Mathieu Bléry; Cécile Bonnafous; Laurent Gauthier; Ariane Morel; Benjamin Rossi; Romain Remark; Violette Breso; Elodie Bonnet; Guillaume Habif; Sophie Guia; Ana Ines Lalanne; Caroline Hoffmann; Olivier Lantz; Jérôme Fayette; Agnès Boyer-Chammard; Robert Zerbib; Pierre Dodion; Hormas Ghadially; Maria Jure-Kunkel; Yannis Morel; Ronald Herbst; Emilie Narni-Mancinelli; Roger B Cohen; Eric Vivier
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

View more
  26 in total

Review 1.  Epigenetic regulation of natural killer cell memory.

Authors:  Colleen M Lau; Gabriela M Wiedemann; Joseph C Sun
Journal:  Immunol Rev       Date:  2021-12-14       Impact factor: 12.988

Review 2.  Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

Authors:  Helen E Heslop; Edward A Stadtmauer; John E Levine; Karen K Ballen; Yi-Bin Chen; Amy E DeZern; Mary Eapen; Mehdi Hamadani; Betty K Hamilton; Parameswaran Hari; Richard J Jones; Brent R Logan; Leslie S Kean; Eric S Leifer; Frederick L Locke; Richard T Maziarz; Eneida R Nemecek; Marcelo Pasquini; Rachel Phelan; Marcie L Riches; Bronwen E Shaw; Mark C Walters; Amy Foley; Steven M Devine; Mary M Horowitz
Journal:  Transplant Cell Ther       Date:  2021-08-27

3.  Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.

Authors:  Han Dong; James Dongjoo Ham; Guangan Hu; Guozhu Xie; Juliana Vergara; Yong Liang; Alaa Ali; Mubin Tarannum; Hannah Donner; Joanna Baginska; Yasmin Abdulhamid; Khanhlinh Dinh; Robert J Soiffer; Jerome Ritz; Laurie H Glimcher; Jianzhu Chen; Rizwan Romee
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-13       Impact factor: 12.779

Review 4.  Natural killer cells and acute myeloid leukemia: promises and challenges.

Authors:  Shayan Rahmani; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Cancer Immunol Immunother       Date:  2022-05-31       Impact factor: 6.630

5.  Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.

Authors:  Melissa M Berrien-Elliott; Jennifer A Foltz; David A Russler-Germain; Carly C Neal; Jennifer Tran; Margery Gang; Pamela Wong; Bryan Fisk; Celia C Cubitt; Nancy D Marin; Alice Y Zhou; Miriam T Jacobs; Mark Foster; Timothy Schappe; Ethan McClain; Samantha Kersting-Schadek; Sweta Desai; Patrick Pence; Michelle Becker-Hapak; Jeremy Eisele; Matthew Mosior; Lynne Marsala; Obi L Griffith; Malachi Griffith; Saad M Khan; David H Spencer; John F DiPersio; Rizwan Romee; Geoffrey L Uy; Camille N Abboud; Armin Ghobadi; Peter Westervelt; Keith Stockerl-Goldstein; Mark A Schroeder; Fei Wan; Wen-Rong Lie; Patrick Soon-Shiong; Allegra A Petti; Amanda F Cashen; Todd A Fehniger
Journal:  Sci Transl Med       Date:  2022-02-23       Impact factor: 19.319

6.  Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Jeffrey P Ward; Melissa M Berrien-Elliott; Felicia Gomez; Jingqin Luo; Michelle Becker-Hapak; Amanda F Cashen; Nina D Wagner-Johnston; Kami Maddocks; Matthew Mosior; Mark Foster; Kilannin Krysiak; Alina Schmidt; Zachary L Skidmore; Sweta Desai; Marcus P Watkins; Anne Fischer; Malachi Griffith; Obi L Griffith; Todd A Fehniger; Nancy L Bartlett
Journal:  Blood       Date:  2022-03-31       Impact factor: 25.476

7.  Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.

Authors:  Lucila N Kerbauy; Nancy D Marin; Mecit Kaplan; Pinaki P Banerjee; Melissa M Berrien-Elliott; Michelle Becker-Hapak; Rafet Basar; Mark Foster; Luciana Garcia Melo; Carly C Neal; Ethan McClain; May Daher; Ana Karen Nunez Cortes; Sweta Desai; Francesca Wei Inng Lim; Mayela Carolina Mendt; Timothy Schappe; Li Li; Hila Shaim; Mayra Shanley; Emily L Ensley; Nadima Uprety; Pamela Wong; Enli Liu; Sonny O Ang; Rong Cai; Vandana Nandivada; Vakul Mohanty; Qi Miao; Yifei Shen; Natalia Baran; Natalie W Fowlkes; Ken Chen; Luis Muniz-Feliciano; Richard E Champlin; Yago L Nieto; Joachim Koch; Martin Treder; Wolfgang Fischer; Oswaldo Keith Okamoto; Elizabeth J Shpall; Todd A Fehniger; Katayoun Rezvani
Journal:  Clin Cancer Res       Date:  2021-05-13       Impact factor: 13.801

8.  Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.

Authors:  Jeffrey J Bednarski; Clare Zimmerman; Melissa M Berrien-Elliott; Jennifer A Foltz; Michelle Becker-Hapak; Carly C Neal; Mark Foster; Timothy Schappe; Ethan McClain; Patrick P Pence; Sweta Desai; Samantha Kersting-Schadek; Pamela Wong; David A Russler-Germain; Bryan Fisk; Wen-Rong Lie; Jeremy Eisele; Stephanie Hyde; Sima T Bhatt; Obi L Griffith; Malachi Griffith; Allegra A Petti; Amanda F Cashen; Todd A Fehniger
Journal:  Blood       Date:  2022-03-17       Impact factor: 25.476

9.  Memory-like Differentiation Enhances NK Cell Responses to Melanoma.

Authors:  Nancy D Marin; Bradley A Krasnick; Michelle Becker-Hapak; Leah Conant; Simon P Goedegebuure; Melissa M Berrien-Elliott; Keenan J Robbins; Jennifer A Foltz; Mark Foster; Pamela Wong; Celia C Cubitt; Jennifer Tran; Christopher B Wetzel; Miriam Jacobs; Alice Y Zhou; David Russler-Germain; Lynne Marsala; Timothy Schappe; Ryan C Fields; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2021-06-29       Impact factor: 12.531

10.  A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.

Authors:  Michelle K Becker-Hapak; Niraj Shrestha; Ethan McClain; Michael J Dee; Pallavi Chaturvedi; Gilles M Leclerc; Lynne I Marsala; Mark Foster; Timothy Schappe; Jennifer Tran; Sweta Desai; Carly C Neal; Patrick Pence; Pamela Wong; Julia A Wagner; David A Russler-Germain; Xiaoyun Zhu; Catherine M Spanoudis; Victor L Gallo; Christian A Echeverri; Laritza L Ramirez; Lijing You; Jack O Egan; Peter R Rhode; Jin-An Jiao; Gabriela J Muniz; Emily K Jeng; Caitlin A Prendes; Ryan P Sullivan; Melissa M Berrien-Elliott; Hing C Wong; Todd A Fehniger
Journal:  Cancer Immunol Res       Date:  2021-07-09       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.